Drug Therapy of Neurovascular Disease

Heart Disease

Volumn 1, Issue 3, 1999, Pages 163-178

  Weinberger, Jesse ^a,c   Terashita, Dawn ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b White Memorial Medical Center   (United States)

^c NORTH GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT;

BRAIN; BRAIN EDEMA; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; HUMAN; MULTIINFARCT DEMENTIA; REVIEW; SEIZURE; VASCULARIZATION;

ANTICOAGULANTS; BRAIN; BRAIN EDEMA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DEMENTIA, VASCULAR; FIBRINOLYTIC AGENTS; HUMAN; NEUROPROTECTIVE AGENTS; PLATELET AGGREGATION INHIBITORS; SEIZURES;

EID: 0033157368     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (176)

1. 133Xenon inhalation. Stroke 1975;6:245-256.
2. Sherman DG, Dyken MJ, Gent M, Harrison MJG, Hart RG, Mohr JP. Antithrombotic therapy for cerebrovascular disorders: an update. Chest 1995;106: 444S-456S.
3. Bogousslavsky J, Van Melle G, Regli F, for the Lausanne Stroke Registry Group. The Lausanne Stroke Registry: analysis of 1000 consecutive patients with first stroke. Stroke 1988;19:1083-1092.
4. Lhermitte F, Gautier JC, Dcrouesne C. Nature of occlusions of the middle cerebral artery. Neurology 1970;20:82-88.
5. Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology 1978;28:973-977.
6. Brickner ME. Cardioembolic stroke. Am J Med 1996;100:465-474.
7. Asinger RW. Incidence of left-ventricular thrombosis after acute transmural myocardial infarction: serial evaluation by 2 dimensional cchocardiography. N Engl J Med 1981;305:297-302.
8. Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology 1965;15:774-778.
9. Bogousslavsky J, Regli F. Unilateral watershed cerebral infarcts. Neurology 1986;36:373-377.
10. Levine S, Payan H. Effects of ischemia and other procedures on the brain and retina of the gerbil (Meriones unguiculatus). Exp Neurol 1966;16:255-262.
11. Burger SK, Saul RF, Selhorst JR, Thurston SE. Transient monocular blindness caused by vasospasm. N Engl JMed 1991;325:870-873.
12. Broderick JP, Swanson JW. Migraine-related strokes. Arch Neurol 1987;44: 868-871.
13. Heros RT, Zervas NT, Varsos V. Cerebral vasospasm after subarachnoid hemorrhage: an update. Ann Neurol 1983;14:599-608.
14. Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine 1968;47:337-369.
15. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993;43:2069-2073.
16. Kohler J, Kasper J, Wirt L, von Reutern G-M. Ischemic stroke due to protein C deficiency. Stroke 1990;21:1077-1080.
17. D'Angelo A, Vigano-D'Angelo S, Esmon CT, Comp RC. Acquired deficiencies of protein S. J Clin Invest 1998;81:1445-1454.
18. Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, Schwartz E. Effect of transfusion therapy on arteriographic abnormalities and on the recurrence of stroke in sickle cell disease. Blood 1984;63:162-169.
19. Cote FM, Yates PO. The occurrence and significance of intracerebral microaneurysms. J Pathol Bacteriol 1967;93:393-401.
20. Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke 1987;18: 311-324.
21. Hart RG, Putnam C. Hemorrhagic transformation of cardioembolic stroke. Stroke 1989;20:1117-1123.
22. Pruitt AA, Rubin RH, Karchmer AW, Duncan GW. Neurologic complications of bacterial endocarditis. Medicine 1978;57:329-351.
23. Silverstein A. Thrombotic thrombocytopenic purpura: the initial neurologic manifestations. Arch Neurol 1968;18:358-362.
24. Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med 1995;333:1392-1400.
25. Kannel WB, Dawber TR, Sorlie P, Wolf PA. Components of blood pressure and risk of atherothrombotic brain infarction: the Framingham Study. Stroke 1976;7:327-331.
26. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressures averaging 90 through 114 mmHg. JAMA 1970;213:1142-1152.
27. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA 1974;229:409-418.
28. The SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3265.
29. Frishman WH, Dhruva N. Systemic hypertension in the elderly: recognition and approaches to therapy. Cardiol Elderly 1994;2:355-361.
30. Gueyffier F, Boutitie F, Boissei JP, Pocock S, Coope J, Cutler J, et al, for the INDANA Investigators. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med 1997;126:761-767.
31. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762.
32. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
33. Kristensen B, Malm J, Carlberg B, Stegmayr B, Backman C, Fagerlund M, et al. Epidemiology and etiology of ischemic stroke in young adults aged 18 to 44 years in northern Sweden. Stroke 1997;28:1702-1709.
34. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979;241:2035-2038.
35. Merimee TJ. Diabetic retinopathy: a synthesis of perspectives. N Engl J Med 1990;322:978-983.
36. Woo J, Lam CWK, Kay R, Wong AH, Teoh R, Nichols MG. The influence of hyperglycemia and diabetes mellitus on immediate and 3 month morbidity and mortality after acute stroke. Arch Neurol 1990;47:1174-1177.
37. Gordon T, Castelli WP, Hjortland MD, Kannel WB, Dawber TR. High-density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977;62:707-714.
38. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638.
39. Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998;32: 140-146.
40. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation 1999;99:216-223.
41. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-1389.
42. Herbert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997;278:313-321.
43. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-950.
44. Bucher HC, Griffith LE, Guyatt GH. Effect of HMG-CoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 1998;128:89-95.
45. Crouse JR, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157:1305-1310.
46. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
47. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the national stroke association. JAMA 1999;281: 1112-1120.
48. Gey KF, Stahelin HB, Eichholzer M. Poor plasma status of carotene and vitamin C is associated with higher mortality from ischemic heart disease and stroke: Basel Prospective Study. Clin Invest 1993;71:3-6.
49. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647-1653.
50. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial (MRFIT). N Engl J Med 1989;320;904-910.
51. Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu heart program. Stroke 1989;20:1460-1465.
52. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
53. Sotelo MM, Johnson SR. The effects of hormone replacement therapy on coronary heart disease. Endocrinol Metab Clin North Am 1997;26:313-328.
54. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.
55. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelet. I. Acetylation of a particular fraction protein. J Clin Invest 1975;56: 624-632.
56. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfin pyrazone in threatened stroke. N Engl J Med 1978;299:53-59.
57. Spranger M, Aspey BS, Harrison MJG. Sex difference in antithrombotic effects of aspirin. Stroke 1989;20:34-37.
58. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-1268.
59. The Swedish Aspirin Low-dose Trial (SALT) Collaborative Group. Swedish aspirin low dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-1349.
60. United Kingdom TIA Study Group. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044-1054.
61. Algra A, van-Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996;60: 197-199.
62. Jonas S, Zeleniuch-Jacquotte A. The effect of antiplatelet agents on survival free of new stroke: a meta-analysis. Stroke Clin Updates 1998;8:1-4.
63. Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998;114:683S-698S.
64. Federal Register 1998;63:56802-56819.
65. Antiplatelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet therapy. Br Med J 1988;296:320-331.
66. Biller J, Feinberg WM, Castaldo JE, Whittemore AD, Harbaugh RE, Dempsey RJ, et al. Guidelines for carotid endarterectomy: a statement for health-care professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke 1998;29:554-562.
67. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995;273: 1421-1428.
68. Cöté R, Battista RN, Abrahamowicz M, Langlois Y, Bourque F, Mackey A, and the Asymptomatic Cervical Bruit Study Group. Lack of effect of aspirin in asymptomatic patients with carotic bruits and substantial carotid narrowing. Ann Intern Med 1995;123:649-655.
69. Brott T, Toole JF. Medical compared with surgical treatment of asymptomatic carotid artery stenosis. Ann Intern Med 1995;123:720-722.
70. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2: 349-360.
71. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-241.
72. Steering Committee of the Physician's Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135.
73. Chinese Acute Stroke Trial (CAST) Collaborative Group. A randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641-1649.
74. The International Stroke Trial (IST) Collaborative Group. A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
75. Johnson M, Walton PL, Cotton RC, Strachan CJL. Pharmacological evaluation of ticlopidine, a novel inhibitor of platelet function. Thromb Haemost 1977;38:64-69.
76. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B, for the Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989;321:501-507.
77. Grotta JC, Norris JW, Kamm B, and the TASS Baseline and Angiographic Data Subgroup. Prevention of stroke with ticlopidine: who benefits most? Neurology 1992;42:1111-1115.
78. Bergamasco B, Benna P, Carolei A, Rasura M, Rudelli G, Rieschi C. A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients: the Ticlopidine Indobufen Stroke Study. Funct Neurol 1997;12:33-43.
79. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220.
80. Fitzgerald GA. Dipyridamole. N Engl J Med 1987;316:1247-1256.
81. Cheseboro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983;51:1537-1543.
82. Acheson J, Danta G, Hutchinson EC. Controlled trial of dipyridamole in cerebral vascular disease. Br Med J 1969;1:614-615.
83. ESPS Group. The European Stroke Prevention Study (ESPS). Stroke 1990;21: 1122-1130.
84. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
85. Tijssen JGP. Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: a review of clinical trial results. Neurolgy 1998;51(suppl 3): S15-S16.
86. Coukell AJ, Markham A. Clopidogrel. Drugs 1997;54:745-751.
87. Caprie Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348: 1329-1339.
88. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br Med J 1964;1:1209-1212.
89. The Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-539.
90. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5.
91. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116: 6-12.
92. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: the Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:587-591.
93. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513-1521.
94. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-152.
95. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1412.
96. Petersen P, Boysen G, Godtfredsen J, Anderson ED, Anderson B, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhaagen AFASAK Study. Lancet 1989;1:175-179.
97. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
98. The Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulation therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-994.
99. The Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;1:499-503.
100. Chimowitz MI, Kokkinos J, Strong J. The warfarin-aspirin symptomatic intracranial disease study. Neurology 1988;45:1488-1493.
101. Wallace JD, Levy LL. Blood pressure after stroke. JAMA 1981;246:2177-2180.
102. Fisher CM. The use of anticoagulants in cerebral thrombosis. Neurology 1958; 8:311-332.
103. Toni D, Riorelli M, Gentile M, Bastianello S, Sacchetti ML, Argentino C, et al. Progressing neurological deficit secondary to acute ischemic stroke: a study on predictability, pathogenesis and prognosis. Arch Neurol 1995;52:670-675.
104. Wittkowsky AK. The stroke pharmacopeia: current medical therapies. Pharmacotherapy 1998;18:94S-100S.
105. Baker RN, Broward JA, Fang HC, Fischer CM, Groch SN, Heyman A, et al. Anticoagulant therapy in cerebral infarction. Neurology 1962;12:823-830.
106. Haley EC Jr., Kassell NF, Torner JC. Failure of heparin to prevent progression in progressing ischemic stroke. Stroke 1988;19:10-14.
107. Duke RJ, Bloch RF, Alexander GG, Turpie AGG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke: a randomized controlled trial. Ann Intern Med 1986;105:825-828.
108. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998;279:1265-1272.
109. Kay R, Wong KS, Ling Y, Chang YW, Tsoi TH, Ahuja AT, et al. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-1593.
110. The Hemodilution in Stroke Study Group. Hypervolemic hemodilution treatment of acute stroke: results of a randomized multicenter trial using pentastarch. Stroke 1989;20:317-323.
111. Aichner FT, Fazekas F, Brainin M, Ploz W, Mamoli B, Zeiler K. Hypervolemic hemodilution in acute ischemic stroke: the Multicenter Austrian Hemodilution Stroke Trial (MAHST). Stroke 1998;29:743-749.
112. Schwab S, Steiner T, Aschoff A, Schwarz S, Steiner HH, Jansen O, et al. Early hemicraniectomy in patients with complete middle cerebral artery infarction. Stroke 1998;29:1888-1893.
113. Koller RL. Recurrent embolic cerebral infarction and anticoagulation. Neurology 1982;32:283-285.
114. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983;14:668-676.
115. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Stroke 1984;15:779-789.
116. Pessin MS, Estol CJ, Lafranchise F, Caplan LR. Safety of anticoagulation after hemorrhagic infarction. Neurology 1993;43:1298-1303.
117. The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994;25:1755-1759.
118. Atkinson RP. Ancrod in the treatment of acute ischaemic stroke. Drugs 1997; 54(suppl 3):100-108.
119. Slater R, Reivich M, Goldberg H, Banka R, Greenberg J. Diaschisis with cerebral infarction. Stroke 1977;8:684-688.
120. Fishman RA. Brain edema. N Engl J Med 1975;293:706-711.
121. Mulley G, Wilcox RG, Mitchell JRA. Dexamethasone in acute stroke. Br Med J 1978;2:994-996.
122. Kieburtz K, Ricotta JJ, Moxley RT III. Seizures following carotid endarterectomy. Arch Neurol 1990;47:568-570.
123. Candelise L, Colombo A, Spinner H. Therapy against brain swelling in stroke patients. Stroke 1975;6:353-355.
124. Mathew NT, Rivera VM, Meyer JS, Charney JZ, Hartmann A. Double-blind evaluation of glycerol therapy in acute cerebral infarction. Lancet 1972;2: 1327-1329.
125. Kilparrick CJ, Davis SM, Tress BM, Rossiter SC, Hopper JL, Vanderdriesen ML. Epileptic seizures in acute stroke. Arch Neurol 1990;47:157-160.
126. Scheuer ML, Pedley TA. The evaluation and treatment of seizures. N Engl J Med 1990;323:1468-1474.
127. Nyenhuis DL, Gorelick PB. Vascular dementia: a contemporary review of epidemiology, diagnosis, prevention, and treatment. J Am Geriatr Soc 1998; 46:1437-1448.
128. Meyer JS, Judd BW, Tawakina T, Rogers RL, Mortel KF. Improved cognition after control of risk factors for multi-intarct dementia. JAMA 1986;256:2203-2209.
129. Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. J Am Geriatr Soc 1989; 37:549-555.
130. Weinberger J. Drug therapy of neurovascular disease. In, Frishman WH, Sonnenblick EH (eds.): Cardiovascular Pharmacotherapeutics. New York: McGraw Hill, 1997;1195-1209.
131. European Pentoxifylline Multi-Infarct Dementia (EPMID) Study Group. The European pentoxifylline multi-infarct dementia study. Eur Neurol 1996;36: 315-321.
132. Marcusson J, Rother M, Kittner B, Rossner M, Smith RJ, Babic T, et al. A 12 month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cognitive Disord 1997;8:320-328.
133. Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol 1996;19:497-506.
134. Nadeau SE, Malloy PF, Andrew ME. A crossover trial of bromocriptinc in the treatment of vascular dementia. Ann Neurol 1988;24:270-272.
135. Multicentre Acute Stroke Trial Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-1514.
136. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-150.
137. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961-966.
138. Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al. Guidelines for thrombolytic therapy for acute stroke, a supplement to guidelines for the management of patients with acute ischemic stroke. Circulation 1996;94:1167-1174.
139. The National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
140. Chiu D, Derk K, Villar-Cordova C, Kasner S, Morgenstern L, Bratina P, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29:18-22.
141. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, vonKummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.
142. Theron J, Courtheoux P, Casasco A, Alachkar F, Notari F, Ganem F, Maiza D. Local intraarterial fibrinolysis in the carotid territory. Am J Neuroradiol 1989; 10:753-766.
143. Zeumer H, Hacke S, Ringelstein EF. Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease. Am J Neuroradiol 1983;4:401-404.
144. del Zoppo G, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998;29:4-11.
145. Sherman DG, for the STAT Writers Group. Defibrination with Viprinex (Ancrod; Kroll Pharmaceuticals) for treatment of acute stroke (abstract). Stroke 1999; 30:234.
146. Rothman S. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci 1984;4:1884-1891.
147. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-513.
148. Siesjo BK. Pathophysiology and treatment of focal cerebral ischemia. I. Pathophysiology. J Neurosurg 1992;77:169-184.
149. Siesjo BK. Pathophysiology and treatment of focal cerebral ischemia. II. Mechanisms of damage and treatment. J Neurosurg 1992;77:337-354.
150. Flamm ES, Demopoulos HB, Seligman ML, Poser RG, Ransohoff J. Free radicals in cerebral ischemia. Stroke 1978;9:445-447.
151. The STIPAS Investigators. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 1994;25:418-423.
152. Clark KWM, Hazel JS, Coull BM. Lazaroids: CNS pharmacology and current research. Drugs 1995;50:971-983.
153. Hickenbottom SL, Grotta J. Neuroprotective therapy. Semin Neurol 1998;18: 485-492.
154. Diener HC, Hacke W, Hennerici M, Radberg J, Hantson L, DeKeyser J. Lubeluzole in acute ischemic stroke: a double-blind placebo controlled phase II trial. Stroke 1996;27:76-81.
155. Alter M for the SASS Investigators. Ganglioside GM-1 in acute ischemic stroke: the SASS trial. Stroke 1994;25:1141-1148.
156. De-Deyn PP, Reuck JD, Deberdt W, Vlietinck R, Orgogozo JM, and Members of the Piracetam in Acute Stroke Study (PASS) Group. Treatment of acute ischemic stroke with piracetam. Stroke 1997;28:2347-2352.
157. Barinaga M. Finding new drugs to treat stroke. Science 1996;272:664-666.
158. Enlimomab Acute Stroke Trial Study Group. The enlimomab acute stroke trial final results (abstract). Neurology 1997;48:A270.
159. Joseph R, Welch KMA. Migraine and platelet: a non-specific association. Headache 1987;27:375-380.
160. Welch KM, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin 1990;8: 817-828.
161. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984; 16:157-168.
162. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-196.
163. Lauritzen M, Olesen TS, Lassen NA, Paulson OB. Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol 1983;13:633-637.
164. Rothrock JF, Walicke P, Swenson MR, Lyden PD, Logan WR. Migrainous stroke. Arch Neurol 1988;45:63-67.
165. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-321.
166. Perry CM, Markham A. Sumatriptan: an updated review of its use in migraine. Drugs 1998;55:889-922.
167. Baumel B. Migraine: a pharmacologic review with newer options and delivery modalities. Neurology 1994;44(Suppl 3):S13-S17.
168. Friedman AP, Elkind AH. Appraisal of methysergide in the treatment of vascular headaches of the migraine type. JAMA 1963;184:125-128.
169. Graham JR, Suby HL, Le Compte PR, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966;274:359-362.
170. Mendizabal JE, Umana E, Zweifler RM. Cluster headache: horton's cephalalgia revisited. South Med J 1998;91:606-617.
171. Poungvarin N, Bhoophat W, Viriyavejakul A, Rodprasert P, Buranasiri P, Sukondhabhant S, et al. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med 1987;316:1229-1233.
172. Hankey G, Hon C. Surgery for primary intracerebral hemorrhage: is it safe and effective? Stroke 1997;28:2126-2132.
173. Teasdale G, Mendelow AD, Graham DI, Harper AM, McCulloch J. Efficacy of nimodipine in cerebral ischemia or hemorrhage. Stroke 1990;21(suppl IV):IV-123-IV-125.
174. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, et al. Cerebral arterial spasm: a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 1983;308:619-624.
175. Haley EC, Kassell, NF, Alves WM, Weir BK, Hansen CA. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage: a report of the Cooperative Aneurysm Study. J Neurosurg 1995;82:786-790.
176. Nibbelink DW. Antihypertensive and antifibrinolytic therapy following subarachnoid hemorrhage from ruptured intracranial aneurysm. In, Sahs AL, Nibbelink DW, Torner JC (eds.): Aneurysmal Subarachnoid Hemorrhage: Report of the Cooperative Study. Volume 13. Baltimore: Urban and Schwarzenberg, 1981;297-306.